Skye Bioscience (SKYE) News Today $2.36 +0.01 (+0.43%) Closing price 04:00 PM EasternExtended Trading$2.35 -0.01 (-0.42%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by BrokeragesSkye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) has been assigned a consensus rating of "Buy" from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 1-year price objective among brokerageMarch 25 at 4:24 AM | marketbeat.comCraig Hallum Lowers Skye Bioscience (NASDAQ:SKYE) Price Target to $14.00March 23 at 2:19 AM | americanbankingnews.comEarnings call transcript: Skye Bioscience Q4 2024 highlights financials, product progressMarch 22 at 3:50 PM | uk.investing.comSkye Bioscience (NASDAQ:SKYE) Price Target Cut to $14.00 by Analysts at Craig HallumCraig Hallum dropped their price target on shares of Skye Bioscience from $18.00 to $14.00 and set a "buy" rating on the stock in a research note on Friday.March 22 at 1:46 PM | marketbeat.comSkye Bioscience's (SKYE) "Outperform" Rating Reiterated at William BlairWilliam Blair restated an "outperform" rating on shares of Skye Bioscience in a research report on Friday.March 22 at 12:18 PM | marketbeat.comSkye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call TranscriptMarch 22 at 9:37 AM | insidermonkey.comSkye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 22 at 2:21 AM | finanznachrichten.deSkye Bioscience price target lowered to $14 from $18 at Craig-HallumMarch 22 at 2:21 AM | markets.businessinsider.comSkye Bioscience’s Positive Earnings Call Highlights Nimacimab ProgressMarch 21, 2025 | tipranks.comSkye Bioscience (NASDAQ:SKYE) Releases Earnings Results, Beats Estimates By $0.06 EPSSkye Bioscience (NASDAQ:SKYE - Get Free Report) issued its earnings results on Thursday. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.06.March 21, 2025 | marketbeat.comSkye Bioscience reports Q4 EPS (24c), consensus (24c)March 21, 2025 | markets.businessinsider.comSkye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment periodMarch 21, 2025 | msn.comSkye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 21, 2025 | finance.yahoo.comSkye Bioscience (NASDAQ:SKYE) Shares Down 31% - Time to Sell?Skye Bioscience (NASDAQ:SKYE) Stock Price Down 31% - Should You Sell?March 21, 2025 | marketbeat.comSkye Bioscience Reports 2024 Financial Results and Trial ProgressMarch 21, 2025 | tipranks.comSkye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comSkye Bioscience to Announce 2024 Financial Results on March 20th, 2025March 14, 2025 | globenewswire.comLeo Miller: Page 4March 7, 2025 | entrepreneur.comSkye Bioscience (NASDAQ:SKYE) Trading Down 2% - Here's WhySkye Bioscience (NASDAQ:SKYE) Trading Down 2% - Here's WhyMarch 1, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Skye Bioscience (SKYE) with Outperform RecommendationMarch 1, 2025 | msn.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of "Buy" from BrokeragesShares of Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) have earned an average recommendation of "Buy" from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year prMarch 1, 2025 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by BrokeragesSkye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) has earned a consensus recommendation of "Buy" from the six brokerages that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 1 year price objective among analystsMarch 1, 2025 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Now Covered by Analysts at William BlairWilliam Blair assumed coverage on shares of Skye Bioscience in a research report on Friday. They set an "outperform" rating for the company.March 1, 2025 | marketbeat.comSkye Bioscience initiated with an Outperform at William BlairFebruary 27, 2025 | markets.businessinsider.comSkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 27, 2025 | globenewswire.comIs This Penny Stock’s 525% Upside Potential an Attainable Goal?February 26, 2025 | msn.comSkye Bioscience Updates Inducement Equity Incentive PlanFebruary 26, 2025 | tipranks.comSkye Bioscience to Participate in SXSW Session on ObesityFebruary 24, 2025 | markets.businessinsider.comWe're Hopeful That Skye Bioscience (NASDAQ:SKYE) Will Use Its Cash WiselyFebruary 22, 2025 | finance.yahoo.comSkye Bioscience to Present at TD Cowen Health Care ConferenceFebruary 20, 2025 | globenewswire.comSkye Bioscience's SWOT analysis: nimacimab's potential reshapes obesity stock landscapeFebruary 17, 2025 | msn.comLeo Miller: Page 3February 12, 2025 | entrepreneur.comSkye Bioscience (NASDAQ:SKYE) Stock Price Up 8.5% - Here's WhySkye Bioscience (NASDAQ:SKYE) Shares Up 8.5% - What's Next?February 7, 2025 | marketbeat.comCraig-Hallum Reaffirms Their Buy Rating on Skye Bioscience (SKYE)February 6, 2025 | markets.businessinsider.comCantor Fitzgerald maintains $14 target on Skye Bioscience stockFebruary 6, 2025 | msn.comCraig-Hallum Remains a Buy on Rezolute (RZLT)February 4, 2025 | markets.businessinsider.comSkye Bioscience Announces Participation in February ConferencesFebruary 4, 2025 | globenewswire.comTop Picks 2025- Skye Bioscience SKYEJanuary 30, 2025 | finance.yahoo.comCantor Fitzgerald Predicts Skye Bioscience FY2025 EarningsSkye Bioscience, Inc. (NASDAQ:SKYE - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Skye Bioscience in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the company will earn ($1.14)January 24, 2025 | marketbeat.comCantor Fitzgerald Forecasts Skye Bioscience FY2025 EarningsSkye Bioscience, Inc. (NASDAQ:SKYE - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Skye Bioscience in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the cJanuary 22, 2025 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Shares Down 2.5% - Time to Sell?Skye Bioscience (NASDAQ:SKYE) Stock Price Down 2.5% - Time to Sell?January 16, 2025 | marketbeat.comSkye Bioscience Provides 2025 Look Ahead and Year in ReviewJanuary 13, 2025 | finance.yahoo.com3 trial readouts that could shake up the obesity market this yearJanuary 8, 2025 | finance.yahoo.comSkye Bioscience (NASDAQ:SKYE) Shares Down 3% - Should You Sell?Skye Bioscience (NASDAQ:SKYE) Shares Down 3% - What's Next?December 26, 2024 | marketbeat.comSkye Bioscience to Present at J.P. Morgan Healthcare ConferenceDecember 19, 2024 | globenewswire.comPiper Sandler Sticks to Its Buy Rating for Skye Bioscience (SKYE)December 16, 2024 | markets.businessinsider.comSkye Bioscience, Inc. (NASDAQ:SKYE) Sees Significant Drop in Short InterestSkye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) was the target of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,590,000 shares, a decrease of 20.1% from the November 15th total of 1,990,000 shares. Based on an average daily trading volume, of 332,600 shares, the short-interest ratio is presently 4.8 days. Approximately 9.1% of the shares of the company are sold short.December 16, 2024 | marketbeat.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of "Buy" from AnalystsShares of Skye Bioscience, Inc. (NASDAQ:SKYE - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price amDecember 14, 2024 | marketbeat.comPoint72 Asset Management L.P. Cuts Position in Skye Bioscience, Inc. (NASDAQ:SKYE)Point72 Asset Management L.P. cut its stake in Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) by 25.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 416,424 shares of the company's stock after selling 143,576 sharesDecember 11, 2024 | marketbeat.comPoint72 Asset Management L.P. Has $1.63 Million Stake in Skye Bioscience, Inc. (NASDAQ:SKYE)Point72 Asset Management L.P. decreased its stake in shares of Skye Bioscience, Inc. (NASDAQ:SKYE - Free Report) by 25.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 416,424 shares of the company's stock afterDecember 11, 2024 | marketbeat.com Remove Ads Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address SKYE Media Mentions By Week SKYE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SKYE News Sentiment▼0.410.63▲Average Medical News Sentiment SKYE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SKYE Articles This Week▼193▲SKYE Articles Average Week Remove Ads Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ESPR News PROK News CRVS News TKNO News ANNX News MBX News CADL News AQST News SEPN News ITOS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SKYE) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SKYE Stock Free SKYE Stock Alerts